 |
|
|
| |
Real World Effectiveness and Cost of Simeprevir- and/or Sofosbuvir-based HCV Treatments
|
| |
| |
Reported by Jules Levin
EASL 2014 April 22-26 Vienna Austria
Kian Bichoupan1, Neeta Tandon2, David Del Bello3, Neal Patel1, Rachana Yalamanchili1, Sweta Chekuri1, Alyson Harty1, Sanders Chang1, Lawrence Ku1, Michel Ng1, David B. Motamed1, Keith M. Sigel1, Donald Gardenier1, Alicia Stivala1, Viktoriya Khaitova1, Meena B. Bansal1, Priya Grewal1, Ritu Agarwal1, Charissa Y. Chang1, Jen Leong1, Gene Y. Im1, Lawrence U. Liu1, Joseph A. Odin1, Nancy Bach1, Scott L. Friedman1, Thomas D. Schiano1, Ponni Perumalswami1, Douglas T. Dieterich1, Andrea D. Branch1
1Division of Liver Diseases, Icahn School of Medicine, New York, NY, United States. 2. Janssen Scientific Affairs, LLC, Titusville, NJ, United States 3. Department of Infectious Diseases, Icahn School of Medicine, New York, NY, United States.
|
| |
|
|
|
|
|
